Vistagen Therapeutics Inc (VTGN)

$0.24 +0.00 (1.20%)
Market Cap 10.83M
Revenue (ttm) 1.27M
Net Income (ttm) -69.69M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -5,487.40%
Debt to Equity Ratio 0.00
Volume 990,700
Avg Vol 4,952,166
Day's Range N/A - N/A
Shares Out 44.38M
Stochastic %K 25%
Beta 0.41
Analysts Hold
Price Target $0.97

Company Profile

Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The company's product pipeline includes Fasedienol, an investigational pherine nasal spray that is in Phase III clinical trial for the treatment of anxiety in adults with social anxiety disorder; and Itruvone, an odorless synthetic investigational neuroactive pherine nasal spray, which is in Phase IIa clinical tria...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 577 3600
Address:
343 Allerton Avenue, South San Francisco, United States
marketCaptain
marketCaptain Aug. 24 at 3:47 PM
$VTGN
0 · Reply
pops132005
pops132005 Aug. 23 at 5:58 PM
$VTGN any real value left here? There's been no announcement from management or anything right.
1 · Reply
nvntr
nvntr Aug. 21 at 2:15 PM
$VTGN Ready for a Strong September Surprise!
0 · Reply
Mp470
Mp470 Aug. 21 at 10:08 AM
$VTGN SRX Global (SRXH) Acquires Stake in Vistagen Therapeutics. we need to know more
0 · Reply
smooth2222
smooth2222 Aug. 20 at 6:48 PM
$VTGN We need partnership news for eother trial, wonder which one they going to go for first?
0 · Reply
13Geo13
13Geo13 Aug. 20 at 5:59 PM
$VTGN
0 · Reply
13Geo13
13Geo13 Aug. 20 at 5:59 PM
$VTGN $SRXH
0 · Reply
Gemini7777
Gemini7777 Aug. 20 at 5:29 PM
$VTGN buy
0 · Reply
marketCaptain
marketCaptain Aug. 20 at 5:26 PM
$VTGN $SRXH About to load more!!
0 · Reply
MikeScottTradingCo
MikeScottTradingCo Aug. 20 at 5:24 PM
$VTGN another 19574 shares in the bank
0 · Reply
Latest News on VTGN
Vistagen Reports Fiscal Year 2027 First Quarter Financial Results and Corporate Update

Aug 14, 2026, 8:32 AM EDT - 10 days ago

Vistagen Reports Fiscal Year 2027 First Quarter Financial Results and Corporate Update

Vistagen Therapeutics Earnings release: Q1 2027

Aug 14, 2026, 8:30 AM EDT - 10 days ago

Vistagen Therapeutics Earnings release: Q1 2027

Vistagen Therapeutics Quarterly report: Q1 2027

Aug 14, 2026, 8:30 AM EDT - 10 days ago

Vistagen Therapeutics Quarterly report: Q1 2027

Vistagen announces topline results from fasedienol repeat dose study

2026-08-06T13:45:38.000Z - 18 days ago

Vistagen announces topline results from fasedienol repeat dose study

Vistagen Announces Topline Results for Repeat Dose Study of Fasedienol for Acute Treatment of Social Anxiety Disorder

Aug 6, 2026, 8:30 AM EDT - 18 days ago

Vistagen Announces Topline Results for Repeat Dose Study of Fasedienol for Acute Treatment of Social Anxiety Disorder

SRX Global acquires stake in Vistagen

2026-08-04T09:10:51.000Z - 20 days ago

SRX Global acquires stake in Vistagen

SRXH

Vistagen Appoints Douglas J. Williamson to its Board of Directors

Jul 31, 2026, 8:30 AM EDT - 24 days ago

Vistagen Appoints Douglas J. Williamson to its Board of Directors

DRUG

Vistagen Therapeutics Proxy statement: Proxy filing

Jul 31, 2026, 8:00 AM EDT - 24 days ago

Vistagen Therapeutics Proxy statement: Proxy filing

Vistagen Therapeutics Proxy statement: Proxy filing

Jul 31, 2026, 8:00 AM EDT - 24 days ago

Vistagen Therapeutics Proxy statement: Proxy filing

Vistagen Therapeutics Transcript: Study update

Jun 30, 2026, 8:30 AM EDT - 7 weeks ago

Vistagen Therapeutics Transcript: Study update

Vistagen Therapeutics Press release: Study update

Jun 30, 2026, 8:30 AM EDT - 7 weeks ago

Vistagen Therapeutics Press release: Study update

Vistagen announces fasedienol did not achieve primary endpoint

2026-06-30T12:05:47.000Z - 7 weeks ago

Vistagen announces fasedienol did not achieve primary endpoint

Vistagen Announces Topline and Post-Hoc Data from PALISADE-4 Phase 3 Public Speaking Challenge Trial of Fasedienol for the Acute Treatment of Social Anxiety Disorder

Jun 30, 2026, 8:00 AM EDT - 7 weeks ago

Vistagen Announces Topline and Post-Hoc Data from PALISADE-4 Phase 3 Public Speaking Challenge Trial of Fasedienol for the Acute Treatment of Social Anxiety Disorder

Vistagen Reports Fiscal Year 2026 Financial Results and Provides Corporate Update

Jun 15, 2026, 4:30 PM EDT - 2 months ago

Vistagen Reports Fiscal Year 2026 Financial Results and Provides Corporate Update

Vistagen Therapeutics Earnings release: Q4 2026

Jun 15, 2026, 4:00 PM EDT - 2 months ago

Vistagen Therapeutics Earnings release: Q4 2026

Vistagen Therapeutics Annual report: Q4 2026

Jun 15, 2026, 4:00 PM EDT - 2 months ago

Vistagen Therapeutics Annual report: Q4 2026

Vistagen announces fasedienol achieves minimum patient exposures

2026-06-09T12:37:17.000Z - 2 months ago

Vistagen announces fasedienol achieves minimum patient exposures

Vistagen Achieves Minimum ICH Safety Exposure Recommendations Across Clinical Program for Fasedienol for the Acute Treatment of Social Anxiety Disorder

Jun 9, 2026, 8:30 AM EDT - 2 months ago

Vistagen Achieves Minimum ICH Safety Exposure Recommendations Across Clinical Program for Fasedienol for the Acute Treatment of Social Anxiety Disorder

Vistagen to Participate in Jefferies 2026 Global Healthcare Conference

May 27, 2026, 8:30 AM EDT - 3 months ago

Vistagen to Participate in Jefferies 2026 Global Healthcare Conference

Vistagen Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2026

May 20, 2026, 2:35 PM EDT - 3 months ago

Vistagen Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2026

Vistagen appoints Angelov as Chief Medical Officer

2026-05-19T12:37:06.000Z - 3 months ago

Vistagen appoints Angelov as Chief Medical Officer

Vistagen Appoints Angel S. Angelov, MD, MBA, as Chief Medical Officer

May 19, 2026, 8:30 AM EDT - 3 months ago

Vistagen Appoints Angel S. Angelov, MD, MBA, as Chief Medical Officer

MD

Vistagen to Participate in the 2026 RBC Capital Markets Global Healthcare Conference

May 14, 2026, 8:30 AM EDT - 3 months ago

Vistagen to Participate in the 2026 RBC Capital Markets Global Healthcare Conference

Vistagen reports preliminary positive data on ongoing PALISADE-3 study

2026-05-12T11:52:14.000Z - 3 months ago

Vistagen reports preliminary positive data on ongoing PALISADE-3 study

Vistagen Announces Preliminary Positive Data in Ongoing Open-Label Extension Portion of PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder

May 12, 2026, 7:30 AM EDT - 3 months ago

Vistagen Announces Preliminary Positive Data in Ongoing Open-Label Extension Portion of PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder

Vistagen announces completion of last patient visit in PALISADE-4 study

2026-05-08T12:22:06.000Z - 3 months ago

Vistagen announces completion of last patient visit in PALISADE-4 study

Vistagen Announces Completion of Last Patient Visit in PALISADE-4 Phase 3 Public Speaking Challenge Study of Fasedienol for Acute Treatment of Social Anxiety Disorder

May 8, 2026, 7:30 AM EDT - 3 months ago

Vistagen Announces Completion of Last Patient Visit in PALISADE-4 Phase 3 Public Speaking Challenge Study of Fasedienol for Acute Treatment of Social Anxiety Disorder

AbCellera target is profile more attractive than Vistagen, says JonesResearch

2026-04-22T14:45:36.000Z - 4 months ago

AbCellera target is profile more attractive than Vistagen, says JonesResearch

ABCL

Vistagen receives FDA ‘Study May Proceed’ letter under refisolone IND filing

2026-04-22T13:41:58.000Z - 4 months ago

Vistagen receives FDA ‘Study May Proceed’ letter under refisolone IND filing

Vistagen Receives FDA “Study May Proceed” Letter Under its Refisolone IND Application, Enabling Further Phase 2 Clinical Development for the Treatment of Vasomotor Symptoms (Hot Flashes) due to Menopause

Apr 22, 2026, 8:30 AM EDT - 4 months ago

Vistagen Receives FDA “Study May Proceed” Letter Under its Refisolone IND Application, Enabling Further Phase 2 Clinical Development for the Treatment of Vasomotor Symptoms (Hot Flashes) due to Menopause

Vistagen Therapeutics Transcript: Stifel 2026 Virtual CNS Forum

Mar 17, 2026, 9:00 AM EDT - 5 months ago

Vistagen Therapeutics Transcript: Stifel 2026 Virtual CNS Forum

Vistagen to Participate in Upcoming Investor Conferences

Mar 3, 2026, 8:30 AM EST - 6 months ago

Vistagen to Participate in Upcoming Investor Conferences

Vistagen Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 3:50 PM EST - 6 months ago

Vistagen Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Vistagen Facing Class Action over Social Anxiety Disorder Drug Claims

2026-02-25T17:53:19.000Z - 6 months ago

Vistagen Facing Class Action over Social Anxiety Disorder Drug Claims

Vistagen to Participate in the 46th Annual TD Cowen Healthcare Conference

Feb 25, 2026, 8:30 AM EST - 6 months ago

Vistagen to Participate in the 46th Annual TD Cowen Healthcare Conference

Vistagen Therapeutics Earnings Call Transcript: Q3 2026

Feb 12, 2026, 5:00 PM EST - 6 months ago

Vistagen Therapeutics Earnings Call Transcript: Q3 2026

Vistagen Therapeutics Quarterly report: Q3 2026

Feb 12, 2026, 5:00 PM EST - 6 months ago

Vistagen Therapeutics Quarterly report: Q3 2026

Vistagen Therapeutics Earnings release: Q3 2026

Feb 12, 2026, 5:00 PM EST - 6 months ago

Vistagen Therapeutics Earnings release: Q3 2026

Vistagen Reports Fiscal Year 2026 Third Quarter Financial Results and Provides Corporate Update

Feb 12, 2026, 4:30 PM EST - 6 months ago

Vistagen Reports Fiscal Year 2026 Third Quarter Financial Results and Provides Corporate Update

VTGN Investors Encouraged to Seek Lead Plaintiff Role in Vistagen Therapeutics Securities Class Actoin Case with Johnson Fistel

Feb 6, 2026, 9:52 AM EST - 7 months ago

VTGN Investors Encouraged to Seek Lead Plaintiff Role in Vistagen Therapeutics Securities Class Actoin Case with Johnson Fistel

Vistagen to Report Fiscal Year 2026 Third Quarter Results and Host Corporate Update Conference Call on February 12, 2026

Feb 4, 2026, 8:30 AM EST - 7 months ago

Vistagen to Report Fiscal Year 2026 Third Quarter Results and Host Corporate Update Conference Call on February 12, 2026

VISTAGEN THERAPEUTICS, INC. (NASDAQ: VTGN) DEADLINE ALERT – Bernstein Liebhard LLP Reminds Vistagen Therapeutics, Inc. Investors of Upcoming Deadline

Jan 22, 2026, 10:45 AM EST - 7 months ago

VISTAGEN THERAPEUTICS, INC. (NASDAQ: VTGN) DEADLINE ALERT – Bernstein Liebhard LLP Reminds Vistagen Therapeutics, Inc. Investors of Upcoming Deadline

VISTAGEN THERAPEUTICS, INC. (NASDAQ: VTGN) INVESTOR ALERT Investors With Large Losses in Vistagen Therapeutics, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights

Jan 16, 2026, 5:06 PM EST - 7 months ago

VISTAGEN THERAPEUTICS, INC. (NASDAQ: VTGN) INVESTOR ALERT Investors With Large Losses in Vistagen Therapeutics, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights

Vistagen downgraded to Hold from Buy at Jefferies

2025-12-17T19:25:24.000Z - 8 months ago

Vistagen downgraded to Hold from Buy at Jefferies

Vistagen downgraded to Hold at Jefferies after social anxiety study miss

2025-12-17T19:25:11.000Z - 8 months ago

Vistagen downgraded to Hold at Jefferies after social anxiety study miss

Vistagen downgraded to Hold from Buy at Maxim

2025-12-17T17:20:14.000Z - 8 months ago

Vistagen downgraded to Hold from Buy at Maxim

Vistagen downgraded to Market Perform from Outperform at William Blair

2025-12-17T16:35:29.000Z - 8 months ago

Vistagen downgraded to Market Perform from Outperform at William Blair

Vistagen downgraded to Market Perform at William Blair after PALISADE-3 miss

2025-12-17T16:35:21.000Z - 8 months ago

Vistagen downgraded to Market Perform at William Blair after PALISADE-3 miss

Vistagen downgraded to Hold at Stifel after PALISADE-3 study disappoints

2025-12-17T15:50:39.000Z - 8 months ago

Vistagen downgraded to Hold at Stifel after PALISADE-3 study disappoints

Vistagen downgraded to Hold from Buy at Stifel

2025-12-17T15:45:17.000Z - 8 months ago

Vistagen downgraded to Hold from Buy at Stifel

Vistagen downgraded to Neutral from Buy at Lucid Capital

2025-12-17T14:40:46.000Z - 8 months ago

Vistagen downgraded to Neutral from Buy at Lucid Capital

Vistagen SAD study did not achieve primary endpoint

2025-12-17T14:05:58.000Z - 8 months ago

Vistagen SAD study did not achieve primary endpoint

Vistagen Announces Topline Results from PALISADE-3 Phase 3 Public Speaking Challenge Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder

Dec 17, 2025, 8:30 AM EST - 8 months ago

Vistagen Announces Topline Results from PALISADE-3 Phase 3 Public Speaking Challenge Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder

Vistagen Appoints Nick Tressler as Chief Financial Officer

Dec 1, 2025, 8:30 AM EST - 9 months ago

Vistagen Appoints Nick Tressler as Chief Financial Officer

Vistagen Reports Findings on PH80's Brain and Autonomic Effects in Women with Menopausal Hot Flashes at The Menopause Society 2025 Annual Meeting

Nov 26, 2025, 8:30 AM EST - 9 months ago

Vistagen Reports Findings on PH80's Brain and Autonomic Effects in Women with Menopausal Hot Flashes at The Menopause Society 2025 Annual Meeting

Vistagen Therapeutics Earnings Call Transcript: Q2 2026

Nov 13, 2025, 5:00 PM EST - 10 months ago

Vistagen Therapeutics Earnings Call Transcript: Q2 2026

Vistagen Therapeutics Quarterly report: Q2 2026

Nov 13, 2025, 5:00 PM EST - 10 months ago

Vistagen Therapeutics Quarterly report: Q2 2026

Vistagen Therapeutics Earnings release: Q2 2026

Nov 13, 2025, 5:00 PM EST - 10 months ago

Vistagen Therapeutics Earnings release: Q2 2026

Vistagen Reports Fiscal Year 2026 Second Quarter Financial Results and Provides Corporate Update

Nov 13, 2025, 4:30 PM EST - 10 months ago

Vistagen Reports Fiscal Year 2026 Second Quarter Financial Results and Provides Corporate Update

Vistagen Therapeutics Transcript: Stifel 2025 Healthcare Conference

Nov 12, 2025, 3:20 PM EST - 10 months ago

Vistagen Therapeutics Transcript: Stifel 2025 Healthcare Conference

Vistagen to Report Fiscal Year 2026 Second Quarter Results and Host Corporate Update Conference Call on November 13, 2025

Nov 10, 2025, 8:30 AM EST - 10 months ago

Vistagen to Report Fiscal Year 2026 Second Quarter Results and Host Corporate Update Conference Call on November 13, 2025

Vistagen to Participate in Stifel Healthcare Conference 2025

Nov 5, 2025, 8:30 AM EST - 10 months ago

Vistagen to Participate in Stifel Healthcare Conference 2025

Vistagen Completes PALISADE-3 Phase 3 Public Speaking Challenge Study for the Acute Treatment of Social Anxiety Disorder

Nov 3, 2025, 8:30 AM EST - 10 months ago

Vistagen Completes PALISADE-3 Phase 3 Public Speaking Challenge Study for the Acute Treatment of Social Anxiety Disorder

Vistagen Appoints Paul Edick to its Board of Directors

Oct 29, 2025, 8:30 AM EDT - 10 months ago

Vistagen Appoints Paul Edick to its Board of Directors

Vistagen to Present at The Menopause Society 2025 Annual Meeting

Oct 16, 2025, 8:30 AM EDT - 11 months ago

Vistagen to Present at The Menopause Society 2025 Annual Meeting

Vistagen Therapeutics Transcript: TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

Sep 18, 2025, 2:20 PM EDT - 1 year ago

Vistagen Therapeutics Transcript: TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

Vistagen Therapeutics Transcript: AGM 2025

Sep 9, 2025, 12:00 PM EDT - 1 year ago

Vistagen Therapeutics Transcript: AGM 2025

Vistagen to Present at the TD Cowen 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

Sep 9, 2025, 8:30 AM EDT - 1 year ago

Vistagen to Present at the TD Cowen 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

Vistagen Therapeutics Earnings Call Transcript: Q1 2026

Aug 7, 2025, 5:00 PM EDT - 1 year ago

Vistagen Therapeutics Earnings Call Transcript: Q1 2026

Vistagen Therapeutics Quarterly report: Q1 2026

Aug 7, 2025, 5:00 PM EDT - 1 year ago

Vistagen Therapeutics Quarterly report: Q1 2026

Vistagen Therapeutics Earnings release: Q1 2026

Aug 7, 2025, 5:00 PM EDT - 1 year ago

Vistagen Therapeutics Earnings release: Q1 2026

Vistagen Reports Fiscal Year 2026 First Quarter Financial Results and Corporate Update

Aug 7, 2025, 4:30 PM EDT - 1 year ago

Vistagen Reports Fiscal Year 2026 First Quarter Financial Results and Corporate Update

Vistagen to Report Fiscal Year 2026 First Quarter Results and Host Corporate Update Conference Call on August 7, 2025

Jul 31, 2025, 8:30 AM EDT - 1 year ago

Vistagen to Report Fiscal Year 2026 First Quarter Results and Host Corporate Update Conference Call on August 7, 2025

Vistagen Therapeutics Proxy statement: Proxy Filing

Jul 28, 2025, 8:00 AM EDT - 1 year ago

Vistagen Therapeutics Proxy statement: Proxy Filing

Vistagen Therapeutics Proxy statement: Proxy Filing

Jul 28, 2025, 8:00 AM EDT - 1 year ago

Vistagen Therapeutics Proxy statement: Proxy Filing

Vistagen to Present at the BTIG Virtual Biotechnology Conference

Jul 24, 2025, 8:30 AM EDT - 1 year ago

Vistagen to Present at the BTIG Virtual Biotechnology Conference

Vistagen Honored for Outstanding Workplace Culture and Mental Health Leadership

Jul 15, 2025, 8:30 AM EDT - 1 year ago

Vistagen Honored for Outstanding Workplace Culture and Mental Health Leadership

Vistagen Appoints Elissa Cote as Chief Corporate Development Officer

Jun 25, 2025, 8:30 AM EDT - 1 year ago

Vistagen Appoints Elissa Cote as Chief Corporate Development Officer

Vistagen Therapeutics Earnings Call Transcript: Q4 2025

Jun 17, 2025, 5:00 PM EDT - 1 year ago

Vistagen Therapeutics Earnings Call Transcript: Q4 2025

Vistagen Therapeutics Earnings release: Q4 2025

Jun 17, 2025, 5:00 PM EDT - 1 year ago

Vistagen Therapeutics Earnings release: Q4 2025

Vistagen Therapeutics Annual report: Q4 2025

Jun 17, 2025, 5:00 PM EDT - 1 year ago

Vistagen Therapeutics Annual report: Q4 2025

Vistagen Reports Fiscal Year 2025 Financial Results and Provides Corporate Update

Jun 17, 2025, 4:30 PM EDT - 1 year ago

Vistagen Reports Fiscal Year 2025 Financial Results and Provides Corporate Update

Vistagen to Report Fiscal Year 2025 Financial Results and Host Corporate Update Conference Call on June 17, 2025

Jun 12, 2025, 8:30 AM EDT - 1 year ago

Vistagen to Report Fiscal Year 2025 Financial Results and Host Corporate Update Conference Call on June 17, 2025

Vistagen Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

Jun 5, 2025, 11:40 AM EDT - 1 year ago

Vistagen Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

Vistagen on Track to Deliver Topline Data From Fasedienol PALISADE-3 Phase 3 Trial for Acute Treatment of Social Anxiety Disorder in the Fourth Quarter of This Year

Jun 2, 2025, 8:30 AM EDT - 1 year ago

Vistagen on Track to Deliver Topline Data From Fasedienol PALISADE-3 Phase 3 Trial for Acute Treatment of Social Anxiety Disorder in the Fourth Quarter of This Year

Vistagen to Present at the Jefferies 2025 Global Life Sciences Conference New York

May 28, 2025, 8:30 AM EDT - 1 year ago

Vistagen to Present at the Jefferies 2025 Global Life Sciences Conference New York

marketCaptain
marketCaptain Aug. 24 at 3:47 PM
$VTGN
0 · Reply
pops132005
pops132005 Aug. 23 at 5:58 PM
$VTGN any real value left here? There's been no announcement from management or anything right.
1 · Reply
nvntr
nvntr Aug. 21 at 2:15 PM
$VTGN Ready for a Strong September Surprise!
0 · Reply
Mp470
Mp470 Aug. 21 at 10:08 AM
$VTGN SRX Global (SRXH) Acquires Stake in Vistagen Therapeutics. we need to know more
0 · Reply
smooth2222
smooth2222 Aug. 20 at 6:48 PM
$VTGN We need partnership news for eother trial, wonder which one they going to go for first?
0 · Reply
13Geo13
13Geo13 Aug. 20 at 5:59 PM
$VTGN
0 · Reply
13Geo13
13Geo13 Aug. 20 at 5:59 PM
$VTGN $SRXH
0 · Reply
Gemini7777
Gemini7777 Aug. 20 at 5:29 PM
$VTGN buy
0 · Reply
marketCaptain
marketCaptain Aug. 20 at 5:26 PM
$VTGN $SRXH About to load more!!
0 · Reply
MikeScottTradingCo
MikeScottTradingCo Aug. 20 at 5:24 PM
$VTGN another 19574 shares in the bank
0 · Reply
Cello69
Cello69 Aug. 20 at 3:58 PM
$VTGN Absolute dogshit
0 · Reply
MikeScottTradingCo
MikeScottTradingCo Aug. 20 at 2:01 PM
$VTGN
0 · Reply
Lacapitana
Lacapitana Aug. 19 at 8:24 PM
$VTGN maybe we will be the MRNA of menopause...
1 · Reply
MikeScottTradingCo
MikeScottTradingCo Aug. 19 at 5:28 PM
$VTGN 157,926 shares and growing… orders in… I’ll be on the board soon
2 · Reply
MikeScottTradingCo
MikeScottTradingCo Aug. 19 at 1:40 PM
$VTGN
0 · Reply
Dirt_Nap_Dead
Dirt_Nap_Dead Aug. 19 at 12:40 PM
$SRXH look at $SMTK and $VTGN .....these are the picks from Eric's little AI video game! If that doesn't tell you he's an idiot scammer that knows nothing, then you bulls are blind sheep...
0 · Reply
To_De_Moon
To_De_Moon Aug. 19 at 8:02 AM
$VTGN very random movemenet lately
0 · Reply
Guido1958
Guido1958 Aug. 18 at 9:02 PM
$VTGN I personally owned 600k at one time. Total scam
3 · Reply
Guido1958
Guido1958 Aug. 18 at 9:01 PM
$VTGN no - this stock is a total scam. SS should be out of this company. 10-20 RS is their only saving grace or a partner which will not happen.
0 · Reply
marketCaptain
marketCaptain Aug. 18 at 8:45 PM
$VTGN This losing 40% from that premarket high at the beginning of month is just unreal
0 · Reply
marketCaptain
marketCaptain Aug. 18 at 6:54 PM
$VTGN Dont push it to low or SRX migh make a refill
0 · Reply
MikeScottTradingCo
MikeScottTradingCo Aug. 18 at 6:38 PM
$VTGN another 7800 shares
0 · Reply